AgomAb Therapeutics
BelgiumEntry
2019
Hold
7yr
Exit
2026
Who owns AgomAb Therapeutics?
AgomAb Therapeutics was owned by Omnes Capital through Omnes Real Tech 1 (2018 vintage) from 2019 to 2026, exited via IPO. Across its history, AgomAb Therapeutics has been through 3 private equity ownership periods, detailed in the timeline below.
Hand-verified · updated 2026-04-21
Most recent investor
Omnes CapitalOmnes Real Tech 1 · 2018 · VC
3 ownership periods · full history below
Key facts
Key takeaways
- ·Fully exited in 2026.
- ·Average hold across 3 realized cycles: 7 years.
Ownership history
3 ownership periods · co-invest detected
Exited
Last exited in 2026.
Co-invest · 3 holders · 2019 · 2026
Boehringer Ingelheim Venture FundExited 2026
2019 · 2026(7yr) · Boehringer Ingelheim Venture Fund · 2010 · Evergreen
IPO
MOIC
–
More from Omnes Real Tech 1
Other portfolio companies in the same fund.
France
Germany
More PE-backed in Biotech
Comparable biotech deals from other GPs.
UK
Track Agomab Therapeutics
Save this record to your watchlist and pick up your research where you left off. No spam.
Get the full record on Agomab Therapeutics.
Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.
Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
Already a member? Sign in
Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue